@Article{096504015X14496932933656,
AUTHOR = {Hao Lu, Chaoyang Sun, Ting Zhou, Bo Zhou, Ensong Guo, Wanying Shan, Meng Xia, Kezhen Li, Danhui Weng, Li Meng, Xiaoyan Xu, Junbo Hu, Ding Ma, Gang Chen},
TITLE = {HSP27 Knockdown Increases Cytoplasmic p21 and Cisplatin Sensitivity  in Ovarian Carcinoma Cells},
JOURNAL = {Oncology Research},
VOLUME = {23},
YEAR = {2015},
NUMBER = {3},
PAGES = {119--128},
URL = {http://www.techscience.com/or/v23n3/57560},
ISSN = {1555-3906},
ABSTRACT = {Drug resistance is the leading cause of chemotherapy failure in the treatment of ovarian cancer. So far, little is 
known about the mechanism of chemoresistance in ovarian cancer. In this study, we explored the mechanism 
that HSP27 was involved in cisplatin resistance of ovarian cancer both in vitro and clinically. HSP27 protein 
was found to be upregulated and expressed in cisplatin-resistant ovarian cancer cell line C13*, and HSP27 
siRNA transfection reversed the chemoresistance of C13*. We found that HSP27 exerted its chemoresistant 
role by inhibiting p21 transferring from the nucleus to the plasma through the activation of phosphorylated-Akt 
pathway. These findings have implications for clinical trials aimed at a potential therapeutic target for ovarian 
tumors that are refractory to conventional treatment.},
DOI = {10.3727/096504015X14496932933656}
}